Phenylketonuria (PKU) Pipeline Review, H2 2016: Therapeutics Review of 7 Companies & 10 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Phenylketonuria (PKU) - Pipeline Review, H2 2016" report to their offering.

Phenylketonuria (PKU) pipeline therapeutics constitutes close to 10 molecules. which approximately 10 molecules are developed by Companies. Our latest report Phenylketonuria - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Phenylketonuria (PKU), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Phenylketonuria (PKU) Phenylketonuria (also called PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head. The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 6 and 3 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Phenylketonuria (PKU) and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Phenylketonuria (PKU) Overview
  3. Therapeutics Development
  4. Pipeline Products for Phenylketonuria (PKU) - Overview
  5. Pipeline Products for Phenylketonuria (PKU) - Comparative Analysis
  6. Phenylketonuria (PKU) - Therapeutics under Development by Companies
  7. Phenylketonuria (PKU) - Therapeutics under Investigation by Universities/Institutes
  8. Phenylketonuria (PKU) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Phenylketonuria (PKU) - Products under Development by Companies
  13. Phenylketonuria (PKU) - Products under Investigation by Universities/Institutes
  14. Phenylketonuria (PKU) - Companies Involved in Therapeutics Development
  • American Gene Technologies International Inc.
  • BioMarin Pharmaceutical Inc.
  • Codexis, Inc.
  • Dimension Therapeutics, Inc.
  • Erytech Pharma SA
  • SOM Innovation Biotech SL
  • Synthetic Biologics, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/h2nhqq/phenylketonuria

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs